ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Silexion Therapeutics Corp
0.3573
-0.0652
-15.43%
盤後：
0.3311
-0.0262
-7.33%
19:58 EDT
成交量：
257.81萬
成交額：
93.53萬
市值：
205.66萬
市盈率：
-0.01
高：
0.3878
開：
0.3600
低：
0.3393
收：
0.4225
52周最高：
46.94
52周最低：
0.3350
股本：
575.59萬
流通股本：
567.23萬
量比：
0.11
換手率：
45.45%
股息：
- -
股息率：
- -
每股收益(TTM):
-56.4473
每股收益(LYR):
-89.5962
淨資產收益率：
-897.46%
總資產收益率：
-123.27%
市淨率：
46.74
市盈率(LYR):
0.00
資料載入中...
總覽
公司
新聞
公告
市場快訊——美股行情動態-Sutro Biopharma、Humacyte
路透中文
·
08/13
Silexion Therapeutics Corp 公布 Sil204 在 KRAS 突變癌細胞中的積極臨床前研究結果
美股速递
·
08/04
Silexion Therapeutics Corp：以色列與德國新站點將加入Sil204 2/3期臨床試驗
美股速递
·
07/29
Silexion Therapeutics 在特拉維夫蘇拉斯基醫療中心成功啓動 Sil204 針對局部晚期胰腺癌的 2/3 期臨床試驗
美股速递
·
07/29
Silexion Therapeutics Corp 宣佈：截至2026年7月29日，已獲以色列Sil204試驗全部監管批准
美股速递
·
07/29
Maxim集團調整目標價至6美元，反映Silexion Therapeutics 1:10並股
美股速递
·
06/24
Silexion Therapeutics Corp在德國獲無條件試驗批准，此前倫理委員會給出積極意見
美股速递
·
06/23
Silexion Therapeutics 公布Sil204針對Kras驅動型胰腺癌免疫療法的積極初步數據
美股速递
·
05/14
Silexion Therapeutics宣佈啓動Sil204的GMP臨床供應生產，並獲特拉維夫Sourasky醫療中心批准2/3期試驗
美股速递
·
05/13
Silexion Therapeutics成功向德國BfArM提交Sil204針對KRAS驅動局部晚期胰腺癌的II/III期臨床試驗申請
美股速递
·
04/28
Silexion Therapeutics計劃本季度末在德國提交2/3期臨床試驗申請，並擬於2027年初在歐盟提交額外監管申請
美股速递
·
03/24
Silexion Therapeutics獲以色列衞生部批准 啓動Sil204治療局部晚期胰腺癌的2/3期臨床試驗
美股速递
·
03/24
Silexion Therapeutics公布2025年第四季度及全年財務業績並更新業務進展
美股速递
·
03/18
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/SLXN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.3573,"timestamp":1789156800000,"preClose":0.4225,"halted":0,"volume":2578057,"hourTrading":{"tag":"盘后","latestPrice":0.3311,"preClose":0.3573,"latestTime":"19:58 EDT","volume":66843,"amount":22796.3153,"timestamp":1789171119712,"change":-0.0262,"changeRate":-0.073328,"amplitude":0.09152},"delay":0,"changeRate":-0.1543195266272189,"floatShares":5672255,"shares":5755900,"eps":-56.4473,"marketStatus":"休市中","change":-0.0652,"latestTime":"09-11 16:00:00 EDT","open":0.36,"high":0.3878,"low":0.3393,"amount":935339.3689085899,"amplitude":0.114793,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-56.4473,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.4225,"preHourTrading":{"tag":"盘前","latestPrice":0.3571,"preClose":0.4225,"latestTime":"09:29 EDT","volume":322000,"amount":116918.7796,"timestamp":1789133392255,"change":-0.0654,"changeRate":-0.154793,"amplitude":0.100355},"postHourTrading":{"tag":"盘后","latestPrice":0.3311,"preClose":0.3573,"latestTime":"19:58 EDT","volume":66843,"amount":22796.3153,"timestamp":1789171119712,"change":-0.0262,"changeRate":-0.073328,"amplitude":0.09152},"volumeRatio":0.10783952465198308},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5672255,"roa":"-123.27%","roe":"-897.46%","lyrEps":-89.596245,"volumeRatio":0.10783952465198308,"shares":5755900,"dividePrice":0,"high":0.3878,"amplitude":0.114793,"preClose":0.4225,"low":0.3393,"week52Low":0.335,"pbRate":"46.74","week52High":46.944,"institutionHeld":0,"latestPrice":0.3573,"eps":-56.4473,"divideRate":0,"volume":2578057,"delay":0,"ttmEps":-56.4473,"open":0.36,"prevYearClose":19.2,"prevWeekClose":0.3518,"prevMonthClose":0.3697,"prevQuarterClose":2.55,"fiveDayClose":0.3516,"twentyDayClose":0.46,"sixtyDayClose":2.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-29","symbol":"SLXN","defaultRemindTime":1780061400000,"type":"split","dateTimestamp":1780027200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-09-11","current":-0.00633,"percent":0.578488,"low":-1.070842,"twenty":-0.527475,"median":-0.257275,"eighty":-0.102281,"high":-0.012403,"avg":-0.326609,"sd":0.240454,"marketCap":2349208},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-27","current":-0.366297,"twenty":-0.584956,"median":-0.430786,"eighty":-0.128959,"marketCap":4363328},{"date":"2026-04-02","current":-0.341131,"twenty":-0.584956,"median":-0.423383,"eighty":-0.129233,"marketCap":4063557},{"date":"2026-04-10","current":-0.310374,"twenty":-0.584956,"median":-0.420859,"eighty":-0.131075,"marketCap":3697171},{"date":"2026-04-17","current":-0.279616,"twenty":-0.584956,"median":-0.417583,"eighty":-0.131655,"marketCap":3330785},{"date":"2026-04-24","current":-0.257275,"twenty":-0.583604,"median":-0.415793,"eighty":-0.131962,"marketCap":3064655},{"date":"2026-05-01","current":-0.171153,"twenty":-0.571093,"median":-0.415025,"eighty":-0.132167,"marketCap":2038773},{"date":"2026-05-08","current":-0.145121,"twenty":-0.564344,"median":-0.413413,"eighty":-0.133702,"marketCap":1728677},{"date":"2026-05-15","current":-0.139472,"twenty":-0.562336,"median":-0.409651,"eighty":-0.135442,"marketCap":1661395},{"date":"2026-05-22","current":-0.12255,"twenty":-0.558738,"median":-0.40296,"eighty":-0.131962,"marketCap":1582122},{"date":"2026-05-29","current":-0.138778,"twenty":-0.557906,"median":-0.397852,"eighty":-0.132133,"marketCap":1791622},{"date":"2026-06-05","current":-0.160977,"twenty":-0.557906,"median":-0.386196,"eighty":-0.133327,"marketCap":2078215},{"date":"2026-06-12","current":-0.100286,"twenty":-0.557906,"median":-0.370491,"eighty":-0.132133,"marketCap":1294694},{"date":"2026-06-18","current":-0.09412,"twenty":-0.552496,"median":-0.356785,"eighty":-0.130188,"marketCap":1215085},{"date":"2026-06-26","current":-0.088602,"twenty":-0.543705,"median":-0.341131,"eighty":-0.128209,"marketCap":1143856},{"date":"2026-07-02","current":-0.083896,"twenty":-0.541677,"median":-0.338335,"eighty":-0.124456,"marketCap":1083102},{"date":"2026-07-10","current":-0.084708,"twenty":-0.536943,"median":-0.320891,"eighty":-0.122887,"marketCap":1093576},{"date":"2026-07-17","current":-0.090225,"twenty":-0.534237,"median":-0.31317,"eighty":-0.120908,"marketCap":1164806},{"date":"2026-07-24","current":-0.077243,"twenty":-0.534237,"median":-0.309392,"eighty":-0.118588,"marketCap":997208},{"date":"2026-07-31","current":-0.059717,"twenty":-0.534237,"median":-0.302127,"eighty":-0.117019,"marketCap":770950},{"date":"2026-08-07","current":-0.058095,"twenty":-0.534237,"median":-0.293597,"eighty":-0.113607,"marketCap":750001},{"date":"2026-08-14","current":-0.014929,"twenty":-0.532214,"median":-0.288004,"eighty":-0.102349,"marketCap":192737},{"date":"2026-08-21","current":-0.158944,"twenty":-0.532214,"median":-0.280777,"eighty":-0.100286,"marketCap":2218542},{"date":"2026-08-28","current":-0.143488,"twenty":-0.530856,"median":-0.278246,"eighty":-0.101584,"marketCap":2002804},{"date":"2026-09-04","current":-0.140062,"twenty":-0.527475,"median":-0.263889,"eighty":-0.102008,"marketCap":1954986},{"date":"2026-09-11","current":-0.168305,"twenty":-0.527475,"median":-0.257275,"eighty":-0.102281,"marketCap":2349208}],"updateTime":1789233050588},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659909279","title":"市場快訊——美股行情動態-Sutro Biopharma、Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909279","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909279?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 00:18","pubTimestamp":1786551516,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI持平于53,793.87点。标普500指数.SPX上涨0.22%，报7,745.57点；纳斯达克综合指数.IXIC上涨0.47%，报26,569.32点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4T4491DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHTR","CRWV","EROC","STRO","BIVI","SLXN","DFTX","GAP","TECH","OFAL","UFO","O","NBIL","OPLN","TPL","SMMT","SMWB","LITE","ANNX","CAVA","NBIX","NCMI","LOCL","NBIS","PFGC","WXM","LQDA","RSPG","LAZR","TSHA","EAT","LITX","NTHI","HUMA","HRB","SLNCF","LUMA","ALT","ABSI","SVV","TRMB","SLN","CIEN","UAMY","DPRE","FSLR","SRHR","BETA","FRNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105446011","title":"Silexion Therapeutics Corp 公布 Sil204 在 KRAS 突變癌細胞中的積極臨床前研究結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1105446011","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105446011?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 21:16","pubTimestamp":1785849395,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 宣布，其在针对 KRAS 突变癌细胞的研究中，取得了关于 Sil204 的积极临床前发现。这一成果为后续的研发工作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197854807","title":"Silexion Therapeutics Corp：以色列與德國新站點將加入Sil204 2/3期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1197854807","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197854807?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:06","pubTimestamp":1785323184,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp披露，预计在未来数月内，将有更多来自以色列和德国的研究中心加入其Sil204 2/3期临床试验项目。这一举措旨在进一步扩大试验的地域覆盖范围，并推动候选药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195302666","title":"Silexion Therapeutics 在特拉維夫蘇拉斯基醫療中心成功啓動 Sil204 針對局部晚期胰腺癌的 2/3 期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1195302666","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195302666?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322910,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics（SLXN）已成功在特拉维夫苏拉斯基医疗中心启动旗下药物 Sil204 的 2/3 期临床试验。该试验聚焦于局部晚期胰腺癌患者，标志着该公司在肿瘤治疗领域迈出关键一步。此次启动不仅验证了前期研究的积累，也为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191362943","title":"Silexion Therapeutics Corp 宣佈：截至2026年7月29日，已獲以色列Sil204試驗全部監管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1191362943","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191362943?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322907,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 正式通报，截至2026年7月29日，该公司已成功获得在以色列开展Sil204试验所需的所有监管批准。这一里程碑式的进展，标志着其研发管线向前迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161346049","title":"Maxim集團調整目標價至6美元，反映Silexion Therapeutics 1:10並股","url":"https://stock-news.laohu8.com/highlight/detail?id=1161346049","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161346049?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 13:41","pubTimestamp":1782279675,"startTime":"0","endTime":"0","summary":"Maxim集团调整了Silexion Therapeutics Corp的目标股价。该机构将目标价从60美元下调至6美元，此举旨在反映公司近期完成的1:10反向股票分割。反向股票分割导致流通股数量减少，每股价格相应调整，因此目标价需进行同步修正以保持可比性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134010182","title":"Silexion Therapeutics Corp在德國獲無條件試驗批准，此前倫理委員會給出積極意見","url":"https://stock-news.laohu8.com/highlight/detail?id=1134010182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134010182?lang=zh_tw&edition=fundamental","pubTime":"2026-06-23 20:41","pubTimestamp":1782218479,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，其在德国的临床试验已获无条件批准。这一决定基于德国伦理委员会此前出具的积极意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158403906","title":"Silexion Therapeutics 公布Sil204針對Kras驅動型胰腺癌免疫療法的積極初步數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1158403906","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158403906?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 21:28","pubTimestamp":1778765302,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 宣布，其针对Kras驱动型胰腺癌的免疫疗法候选药物Sil204，取得了积极的初步研究结果。这一发现为这一难治性癌症领域的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187044421","title":"Silexion Therapeutics宣佈啓動Sil204的GMP臨床供應生產，並獲特拉維夫Sourasky醫療中心批准2/3期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1187044421","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187044421?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 20:02","pubTimestamp":1778673723,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics公司宣布，已与一家领先的全球合同开发与生产组织（CDMO）合作，启动了其候选药物Sil204的GMP临床供应生产。与此同时，公司还获得了来自以色列特拉维夫Sourasky医疗中心对其Sil204药物进行2/3期临床试验的新批准。这两项进展标志着该药物临床开发路径上的重要里程碑，为其后续的临床研究推进提供了关键的物料支持和试验场地保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194280405","title":"Silexion Therapeutics成功向德國BfArM提交Sil204針對KRAS驅動局部晚期胰腺癌的II/III期臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1194280405","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194280405?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 20:48","pubTimestamp":1777380512,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp（简称SLXN）宣布，已顺利完成其核心候选药物Sil204针对KRAS基因驱动型局部晚期胰腺癌的II/III期临床试验申请，并正式提交至德国联邦药品和医疗器械研究所（BfArM）。这一关键进展标志着该创新疗法向临床验证迈出重要一步，为全球胰腺癌患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128273196","title":"Silexion Therapeutics計劃本季度末在德國提交2/3期臨床試驗申請，並擬於2027年初在歐盟提交額外監管申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1128273196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128273196?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:39","pubTimestamp":1774355952,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，计划在本季度末前向德国监管机构提交其2/3期临床试验的申请。此外，公司还预计将在2027年初于欧盟范围内提交额外的监管申请文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158550340","title":"Silexion Therapeutics獲以色列衞生部批准 啓動Sil204治療局部晚期胰腺癌的2/3期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158550340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158550340?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:38","pubTimestamp":1774355925,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp已正式获得以色列卫生部批准，将启动其核心候选药物Sil204针对局部晚期胰腺癌的2/3期临床试验。这一关键监管许可标志着该药物临床开发进程中的重要一步，为评估其在治疗这一难治性癌症方面的潜力铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112627847","title":"Silexion Therapeutics公布2025年第四季度及全年財務業績並更新業務進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1112627847","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112627847?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 05:02","pubTimestamp":1773781344,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp公布了2025年第四季度及全年的财务业绩，并同步更新了公司最新的业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}